CN102805862A - 一种vero细胞培养新布尼亚病毒纯化灭活疫苗的制备方法 - Google Patents
一种vero细胞培养新布尼亚病毒纯化灭活疫苗的制备方法 Download PDFInfo
- Publication number
- CN102805862A CN102805862A CN2012101214719A CN201210121471A CN102805862A CN 102805862 A CN102805862 A CN 102805862A CN 2012101214719 A CN2012101214719 A CN 2012101214719A CN 201210121471 A CN201210121471 A CN 201210121471A CN 102805862 A CN102805862 A CN 102805862A
- Authority
- CN
- China
- Prior art keywords
- virus
- cell
- culture
- vero
- purification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003501 vero cell Anatomy 0.000 title claims abstract description 31
- 229960005486 vaccine Drugs 0.000 title claims abstract description 26
- 238000000746 purification Methods 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 241001535172 Severe fever with thrombocytopenia virus Species 0.000 title abstract description 7
- 230000002779 inactivation Effects 0.000 title abstract description 5
- 238000004113 cell culture Methods 0.000 title description 8
- 241000700605 Viruses Species 0.000 claims abstract description 84
- 210000004027 cell Anatomy 0.000 claims abstract description 43
- 238000011218 seed culture Methods 0.000 claims abstract description 22
- 239000007788 liquid Substances 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 20
- 238000011081 inoculation Methods 0.000 claims abstract description 10
- 230000003321 amplification Effects 0.000 claims abstract description 5
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 5
- 241000713112 Orthobunyavirus Species 0.000 claims description 23
- 230000003612 virological effect Effects 0.000 claims description 15
- 230000009849 deactivation Effects 0.000 claims description 8
- 229940031551 inactivated vaccine Drugs 0.000 claims description 8
- 239000005723 virus inoculator Substances 0.000 claims description 8
- 238000003556 assay Methods 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 238000005096 rolling process Methods 0.000 claims description 7
- 239000001963 growth medium Substances 0.000 claims description 6
- 238000012856 packing Methods 0.000 claims description 6
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 claims description 5
- 229960000380 propiolactone Drugs 0.000 claims description 5
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 4
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 239000012930 cell culture fluid Substances 0.000 claims description 4
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 3
- 238000011534 incubation Methods 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 239000002435 venom Substances 0.000 claims description 3
- 231100000611 venom Toxicity 0.000 claims description 3
- 210000001048 venom Anatomy 0.000 claims description 3
- 239000012531 culture fluid Substances 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 231100000614 poison Toxicity 0.000 claims description 2
- 239000002574 poison Substances 0.000 claims description 2
- 239000003223 protective agent Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000036039 immunity Effects 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 201000001916 Hypochondriasis Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 241000150350 Peribunyaviridae Species 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 201000000239 Phlebotomus fever Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000008383 multiple organ dysfunction Effects 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000029305 taxis Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
分离时间 | 分离省份 | 分离标本 | 分离时用细胞 | |
JS-2007-001 | 2011-04-01 | 江苏 | 病人血清 | Vero |
JS-2010-004 | 2010-06-13 | 江苏 | 病人血清 | Vero |
JS-2010-014 | 2010-10-11 | 江苏 | 病人血清 | Vero |
JS-2010-018 | 2010-11-26 | 安徽 | 病人血清 | Vero |
JS-2010-026 | 2010-11-22 | 江苏 | 病人血清 | Vero |
JS-2010-DOG | 2011-01-14 | 江苏 | 可疑病犬脾脏 | Vero |
JS-2011-013 | 2011-06-15 | 江苏 | 病人血清 | Vero |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210121471.9A CN102805862B (zh) | 2012-04-24 | 2012-04-24 | 一种vero细胞培养新布尼亚病毒纯化灭活疫苗的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210121471.9A CN102805862B (zh) | 2012-04-24 | 2012-04-24 | 一种vero细胞培养新布尼亚病毒纯化灭活疫苗的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102805862A true CN102805862A (zh) | 2012-12-05 |
CN102805862B CN102805862B (zh) | 2015-01-07 |
Family
ID=47229845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210121471.9A Active CN102805862B (zh) | 2012-04-24 | 2012-04-24 | 一种vero细胞培养新布尼亚病毒纯化灭活疫苗的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102805862B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103063854A (zh) * | 2013-01-10 | 2013-04-24 | 中国农业科学院兰州兽医研究所 | 一种鸭坦布苏病毒抗体固相竞争elisa检测试剂盒 |
CN113337477A (zh) * | 2021-05-31 | 2021-09-03 | 李家斌 | 一种发热伴血小板减少综合征病毒株的分离方法 |
CN113337475A (zh) * | 2021-05-27 | 2021-09-03 | 罗益(无锡)生物制药有限公司 | 一种出血热疫苗生产及纯化工艺 |
CN114929855A (zh) * | 2019-12-24 | 2022-08-19 | 株式会社Lg化学 | 用于培养vero细胞的低血清培养基组合物及其用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1248471A (zh) * | 1998-09-23 | 2000-03-29 | 卫生部北京生物制品研究所 | Vero细胞乙型脑炎灭活疫苗及其制备方法 |
-
2012
- 2012-04-24 CN CN201210121471.9A patent/CN102805862B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1248471A (zh) * | 1998-09-23 | 2000-03-29 | 卫生部北京生物制品研究所 | Vero细胞乙型脑炎灭活疫苗及其制备方法 |
Non-Patent Citations (3)
Title |
---|
XUE-JIE YU,ET AL: "Fever with Thrombocytopenia Associated with a Novel Bunyavirus in China", 《THE NEW ENGLAND JOURNAL OF MEDICINE》 * |
杜燕华等: "新布尼亚病毒在非洲绿猴肾细胞中的培养与分离鉴定", 《中华预防医学杂志》 * |
马亦林: "人类感染新型布尼亚病毒近况", 《中华临床感染病杂志》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103063854A (zh) * | 2013-01-10 | 2013-04-24 | 中国农业科学院兰州兽医研究所 | 一种鸭坦布苏病毒抗体固相竞争elisa检测试剂盒 |
CN114929855A (zh) * | 2019-12-24 | 2022-08-19 | 株式会社Lg化学 | 用于培养vero细胞的低血清培养基组合物及其用途 |
CN113337475A (zh) * | 2021-05-27 | 2021-09-03 | 罗益(无锡)生物制药有限公司 | 一种出血热疫苗生产及纯化工艺 |
CN113337477A (zh) * | 2021-05-31 | 2021-09-03 | 李家斌 | 一种发热伴血小板减少综合征病毒株的分离方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102805862B (zh) | 2015-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102258776B (zh) | 猪肺炎支原体、猪鼻支原体二联灭活疫苗及其制备方法 | |
CN104099301B (zh) | 柯萨奇病毒a16型病毒株、用途、疫苗及其制备方法 | |
CN102258777B (zh) | 用鸡胚源细胞系繁殖传染性法氏囊病毒制备灭活疫苗和联苗的方法 | |
CN103083654A (zh) | Celligen310生物反应器制备人二倍体细胞狂犬病疫苗工艺 | |
CN102816740B (zh) | 一种禽流感病毒、灭活疫苗及其制备方法 | |
CN103497934B (zh) | 鸡传染性支气管炎病毒疫苗株(hf2株)及其应用 | |
CN102805862B (zh) | 一种vero细胞培养新布尼亚病毒纯化灭活疫苗的制备方法 | |
CN104338127A (zh) | 一种h9n2亚型禽流感灭活疫苗的生产方法及其制品 | |
CN104087559B (zh) | 一种传染性法氏囊病毒、灭活疫苗及其制备方法 | |
CN103923885B (zh) | 鸡传染性法氏囊病毒Vero细胞适应株及其应用 | |
CN107164273B (zh) | 一种免疫原性强的血清2型猪链球菌及其应用 | |
CN106834168B (zh) | 一种猪链球菌2型弱毒株及其应用 | |
CN103751772A (zh) | 一种制备f基因型腮腺炎减毒活疫苗的方法 | |
CN104069489B (zh) | 鸡新城疫和传染性法氏囊二联灭活疫苗及其制备方法 | |
CN104164408A (zh) | 抗鸡新城疫、传染性支气管炎和禽流感疫苗组合物及制备 | |
CN104208666A (zh) | 一种疫苗组合物及其制备方法和应用 | |
CN102805863B (zh) | 一种人二倍体细胞培养新布尼亚病毒纯化灭活疫苗的制备方法 | |
CN103160475B (zh) | 一种肠道病毒71型病毒株及其用途、疫苗和制备方法 | |
CN102343088B (zh) | 一种犬传染性气管支气管炎二联活疫苗及其制备方法 | |
CN104031888B (zh) | 鸡新城疫病毒弱毒株、灭活疫苗及其应用 | |
CN103160474B (zh) | 肠道病毒71型病毒株、疫苗、动物模型建立方法 | |
CN111551747A (zh) | 基于抗体检测用兔检验猪塞内卡病毒病灭活疫苗效力的方法 | |
CN104248758A (zh) | 一种疫苗组合物及其制备方法和应用 | |
CN111057683A (zh) | 一种鸡胚接种用病毒稀释液及其制备方法和应用 | |
CN103436497B (zh) | 一种猪细小病毒毒株 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: WUXI XINLIANXIN BIOMEDICINE TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: WAN LIMING Effective date: 20150803 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150803 Address after: 214142 Jiangsu New District of Wuxi City Linghu Road No. 97, building B-2, Inc. Patentee after: WUXI XINLIANXIN BIOLOGICAL PHARMACEUTICAL CO., LTD. Address before: 214121, Jiangsu Province, Wuxi Binhu District Vanke City Garden District 282-1702, room two Patentee before: Wan Liming |
|
DD01 | Delivery of document by public notice |
Addressee: WUXI XINLIANXIN BIOLOGICAL PHARMACEUTICAL CO., LTD. Document name: Notification of Passing Examination on Formalities |